Barbara Jane Klencke MD
Breast Cancer, HIV/AIDS Related, Hematologic Oncology
SVP, Development, Onyx Pharmaceuticals
Join to View Full Profile
Onyx Pharmaceuticals249 E Grand AveSouth San Francisco, CA 94080
Phone+1 650-266-1008
Dr. Klencke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Internship, Internal Medicine, 1990 - 1991
University of California San Diego School of MedicineClass of 1990
Clinical Trials
- EMD 121974 in Treating Patients With HIV-Related Kaposi's Sarcoma Start of enrollment: 2000 Sep 01
- A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) Start of enrollment: 2003 Jul 01
Publications & Presentations
PubMed
- 55 citationsClinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conju...Manish Gupta, Patricia LoRusso, Bei Wang, Joo-Hee Yi, Howard A. Burris
Journal of Clinical Pharmacology. 2012-05-01 - 529 citationsPhase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior ...Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, Rachel A. Borson
Journal of Clinical Oncology. 2011-02-01 - 91 citationsSafety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label studyW. K. Alfred Yung, James J. Vredenburgh, Timothy F. Cloughesy, Phioanh L. Nghiemphu, Barbara Klencke
Neuro-Oncology. 2010-10-01
Press Mentions
eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateNovember 8th, 2021- Sierra Oncology Hosting KOL Panel Event to Discuss Momelotinib Data Presented at EHA 2021June 14th, 2021
FDA Grants Fast-Track Designation to Bone Marrow Cancer DrugJune 7th, 2019- Join now to see all
Grant Support
- Plasmid DNA Vaccine To HPV-16 For Anal DysplasiaNational Center For Research Resources2000–2002
- ONYX-015 For HIV Associated Preinvasive Anal CarcinomaNational Center For Research Resources2000–2002
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
